Project Grant R01AR085886
Award Date
7/10/25
Completion Date
5/31/28
Dollars Obligated
$241K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This federal Project Grant award, totaling $317,476.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award will support research at the University of Alabama at Birmingham (UAB) to investigate the molecular genetic causes of gout flares. The project aims to conduct differential gene expression analysis of myeloid cell subsets in peripheral blood and...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), provides $228,218 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 12-week randomized controlled trial evaluating the serum urate-lowering effects of the SGLT2 inhibitor empagliflozin versus placebo in 60 gout patients with...
This federal Project Grant award of $765,546, awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to develop a novel non-invasive method for assessing bone turnover in patients with chronic kidney disease (CKD). The project aims to evaluate a "virtual bone biopsy" approach using time-lapse high-resolution peripheral quantitative computed...
This federal Project Grant award of $671,986 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to strengthen the evidence-base for medication prescribing in older adults with chronic kidney disease (CKD). The primary objectives are to: 1) Evaluate the effectiveness of renoprotective therapies, such as angiotensin converting enzyme inhibitors (ACEIs) and sodium-glucose...
This federal Project Grant award of $176,040.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award will fund research by Dr. Naomi J. Patel, an Instructor in Medicine at Harvard Medical School and Rheumatologist at Massachusetts General Hospital, to assess the impact of different glucocorticoid (GC) regimens on GC toxicity. The goals are to: 1) evaluate...
This federal Project Grant award, valued at $828,682 and awarded on September 24, 2024, supports research into population-based outcomes for rheumatoid arthritis (RA) in rural health settings. The funding is provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to investigate the challenges rural residents face in timely RA diagnosis and treatment...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding research to investigate the mechanistic links between gait biomechanics and the development of knee osteoarthritis (KOA). The $644,152 award, which runs from January 2025 to December 2029, will be used by the University of North Carolina at Chapel Hill to: 1) determine the acute in vivo...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $298,915 to Cyrus Biotechnology, Inc. to develop advanced uricase enzyme variants for improved treatment of gout. The key objectives are to engineer uricase proteins with enhanced stability, reduced immunogenicity, and extended half-life, which can address the limitations of current...
This $578,944 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The primary objective is to decipher the genetics of osteoarthritis (OA) susceptibility, heterogeneity, and progression. The research aims to identify new and fine-map known genetic loci associated with OA and total joint replacement, disentangle OA heterogeneity by...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $297,940 to Case Western Reserve University from August 15, 2024 to July 31, 2026. The purpose is to develop patient- and parent-driven outcome measures for evaluating glandular inflammation and its flares, and their impact on quality of life and mental health for clinical trials related to...